Capital Health Regional Medical Center First Hospital in Country to Use Trevo™ , an Investigational Device Developed For Clot Removal in Stroke Patients


February 15, 2011

Trenton, NJ - Capital Health Regional Medical Center last week became the first hospital in the country to treat a patient using Trevo™ , an investigational device being used to remove blood clots in patients suffering from acute ischemic stroke, where a blood clot, or thrombus, blocks the flow of blood to the brain. The Trevo Retriever is a device utilizing Stentriever™ technology.

The device was used by Capital Health cerebrovascular endovascular neurosurgeon, Dr. Kenneth Liebman as part of TREVO 2, a study that looks to compare Trevo, an experimental device and the Merci Retriever™, a device which has already been approved by the FDA to remove clots. The goal of the study is to determine the success of Trevo in removing the blood clot blocking blood flow, and how well patients do following the use of it in comparison to those treated using Merci.

“The options for treating stroke patients have continued to grow in recent years and it is critical that we continue to push forward and test new ways to effectively help patients,” said Dr. Liebman who is director of Neurosurgical Critical Care at Capital Health.

Dr. Erol Veznedaroglu, director, Neurosciences and Endovascular & Cerebrovascular Neurosurgery at Capital Health and principal investigator on the TREVO 2 study added, “With a time critical disease like stroke, patients need treatment fast and having a broad range of treatment options available is essential to providing patients with the best chance at surviving and limiting associated disabilities. And, for us as physicians, constantly advancing the tools available to us enables us to more effectively treat these patients.”

Both devices are products developed by Concentric Medical. The Merci Retriever, one of the first devices used for clot retrieval in ischemic stroke patients, is shaped like a corkscrew that captures and removes the clot. Trevo combines a stent-like shaped section with retrieval capabilities.

Patients impacted by ischemic stroke are able to be treated initially by IV tPA, a clot busting drug, if it is administered in a relatively short window of three hours after symptoms begin. After that window, or if tPA is not successful, patients may be candidates for intra-arterial mechanical thrombectomy (clot removal).

Mechanical thrombectomy is a minimally invasive procedure performed to attempt removal of the clot. It is done endovascularly through a small incision in the groin. Following the incision, a guidewire and microcatheter are navigated through the femoral artery into the blood vessel containing the clot. At that point a device is deployed to entrap the clot and remove it from the body.

Capital Health neurosurgeons have participated in multiple clinical trials to test new devices to treat stroke and other cerebrovascular diseases. Late last year, the hospital became the first hospital in Southern/Central New Jersey and the Philadelphia region to treat a patient using the Solitaire™ FR Revascularization Device, an investigational device also being studied for use in clot removal.

Coordinating the study’s implementation at Capital Health are Kristen Smith, clinical research coordinator for Neurosciences, and Cynthia Lewis-Diaz, clinical research nurse.

Capital Health Regional Medical Center is a state designated Comprehensive Stroke Center, which establishes the hospital as a leader in providing advanced care for patients suffering from stroke. Capital Health Mercer is a state designated primary stroke center. Capital Health’s two hospitals have also received certification from The Joint Commission -- the gold standard for stroke care. The hospital system has also been awarded the American Heart Association/American Stroke Association’s Get With The Guidelines® Stroke Gold Plus Performance Achievement Award, for excellence in stroke care.

Capital Health is also home of the Stroke and Cerebrovascular Center of New Jersey, which gives the hospital an even greater ability to treat the most critical cerebrovascular patients utilizing the most advanced technologies and treatments.
Back to top